Alexza’s Acute-Panic Drug Fails In Phase IIa
This article was originally published in The Pink Sheet Daily
Executive Summary
Inhaled therapy missed both primary endpoints, but lead candidate has finished Phase III schizophrenia enrollment early.
You may also be interested in...
Revised Alexza Deal Suggests Updated Strategy For Symphony Capital
With the dissolution of Symphony Allegro and the return of the joint venture's three clinical programs to Alexza, Symphony Capital should have its exit from the $50 million investment it made in the biotech and its Staccato aerosol inhalation technology in 2006
Revised Alexza Deal Suggests Updated Strategy For Symphony Capital
With the dissolution of Symphony Allegro and the return of the joint venture's three clinical programs to Alexza, Symphony Capital should have its exit from the $50 million investment it made in the biotech and its Staccato aerosol inhalation technology in 2006
Troubled Biotechs: Alexza, Synvista, Alseres, Bionovo
Alexza says its restructuring should keep it operating well into 2010, but three other companies probably have less time.